AICROS

Contact Us

Biostatistics

Advanced Biostatistics Services: Powering Decisions in Clinical Trials

The difference between successful drug development and costly delays often lies in the quality of the data analysis. Our biostatistics clinical trials services provide the scientific rigor needed to transform complex clinical data into reliable, regulatory-ready evidence. We are the architects of your trial’s logic, ensuring your study design is sound, your data is interpreted correctly, and your results are communicated clearly to global health authorities.

As a trusted global Clinical Research Organization (CRO), our biostatisticians are integrated into every phase of your project, from protocol concept to final submission, guaranteeing seamless scientific continuity and compliance.

1. Biostatistical Consulting and Trial Design

Our expertise begins long before the first patient is enrolled. Proactive biostatistical consulting is crucial to building a trial that is both efficient and scientifically defensible.

  • Protocol Development & Statistical Input: We collaborate with you to define the study objectives, endpoints, and hypotheses. We translate your scientific goals into a statistically sound trial design, including randomization, blinding strategies, and complex adaptive designs.
  • Sample Size and Power Calculation: We use sophisticated modeling to determine the optimal number of subjects required for your study. This ensures the trial is neither underpowered (unable to detect a true effect) nor overpowered (wasteful of time and resources), providing the necessary statistical power to achieve primary endpoints.

Regulatory Strategy: Our biostatisticians possess in-depth knowledge of global regulatory guidelines (FDA, EMA, ICH), ensuring that your trial design and analysis approach adhere to the highest international standards from the outset.

2. Statistical Analysis Plan (SAP) Development

The statistical analysis plan (SAP) is the critical blueprint for your trial’s analysis. Developed in conjunction with the final protocol, the SAP ensures that all planned analyses are predefined, removing potential bias and guaranteeing transparency.

  • Comprehensive Documentation: We draft the detailed, finalized SAP before any unblinded data analysis begins. This document specifies all statistical methods, data handling rules, definition of analysis populations (e.g., Intent-to-Treat, Per-Protocol), and procedures for handling missing data.
  • Mock Tables, Listings, and Figures (TLFs): The SAP includes mock-ups of all planned Tables, Listings, and Figures. This proactive step ensures that all stakeholders agree on the exact format of the final results, streamlining the reporting phase and preventing miscommunication.

Interim Analysis Support: For trials requiring interim data reviews or independent Data Monitoring Committee (iDMC) support, our biostatisticians develop robust charter documents and detailed statistical plans to manage decision-making boundaries, control Type I error rates, and maintain the integrity of the blinded study.

3. Clinical Data Analysis and Programming Expertise

Execution of the SAP relies on precise programming and expert data analysis. We ensure seamless execution through our specialized programming capabilities.

  • Statistical Programming: Our team of expert SAS programming specialists (the industry-standard language) and R programmers are highly skilled in developing and validating code. They generate all necessary analysis datasets, tables, listings, and figures with unparalleled accuracy.
  • Data Standardization (CDISC): We leverage our partnership with Data Management to ensure all datasets are structured according to CDISC standards (SDTM and ADaM), which are required for regulatory submission. Our programmers are experts at generating these compliant analysis datasets for both efficiency and ease of review by regulatory agencies.

Advanced Methodologies: Our biostatisticians are experienced in a full range of complex methodologies, including survival analysis (e.g., Kaplan-Meier, Cox proportional hazards models), mixed models for repeated measures (MMRM), Bayesian statistics, meta-analyses, and health economics outcomes research (HEOR). This allows us to handle the most intricate and challenging trial data.

4. Reporting, Communication, and Regulatory Submission

The final step is the clear and confident communication of your results. Our team ensures that your findings are presented accurately and ready for regulatory scrutiny.

  • Statistical Report Writing: Following clinical data analysis and database lock, we draft the comprehensive statistical report section of the Clinical Study Report (CSR). This narrative provides the statistical interpretation of the results, detailing all methods, findings, and conclusions, which is the cornerstone of your submission package.
  • Integrated Summary of Safety/Efficacy (ISS/ISE): For final regulatory submissions (e.g., NDAs/BLAs), we design and execute pooled analyses across multiple studies to provide a robust summary of the overall safety and efficacy profile of your product.
  • Expert Representation: Our biostatisticians are prepared to support you through meetings and discussions with regulatory bodies, including the FDA and EMA. We provide the expert scientific defense necessary to address complex statistical queries and confidently move your product toward approval.

By choosing our biostatistics clinical trials services, you gain a partner committed to delivering scientific integrity, compliance, and strategic foresight at every phase of your product’s journey.